Seaport Therapeutics and Hemab filed simultaneous S-1 amendments this week, pricing initial public offerings worth a combined $180 million to advance depression and clotting disorder programs into late-stage trials. Seaport's offering accounts for $100 million, targeting a valuation near $500 million pre-money, while Hemab pursues $80 million at a $320 million pre-money mark. Both companies plan to list on Nasdaq within fourteen days, according to Renaissance Capital's IPO calendar.
Seaport's lead candidate, SPI-62, is a GABA-A receptor modulator in Phase 2b trials for major depressive disorder with 240 patients enrolled across 32 U.S. sites. Topline data is scheduled for Q3 2025. The company holds exclusive licenses from Genentech covering five neuropsychiatric indications, with milestone payments capped at $450 million plus mid-single-digit royalties. Hemab's core asset, HMB-001, is a monoclonal antibody targeting Factor XI for venous thromboembolism prevention, currently in Phase 2 with 180 patients across European and North American centers. Results are expected Q4 2025. Hemab's IP portfolio includes 14 issued patents expiring between 2038 and 2041.
The timing reflects capital-market positioning ahead of a crowded biotech IPO window. Twelve healthcare offerings are queued for Q2 2025, the largest cohort since Q1 2021, when 19 biotechs priced within a single quarter. Institutional pre-marketing for both companies began March 17, with books closing April 2. Lead underwriters are JPMorgan for Seaport and Jefferies for Hemab. Seaport's offering includes a 15% greenshoe, potentially raising the total to $115 million. Hemab's structure is fixed at $80 million with no overallotment provision. Both companies entered quiet periods with burn rates near $18 million quarterly, implying eighteen-month runways at midpoint pricing.
Allocators should note three factors. First, Seaport's Genentech relationship provides both validation and cap-table complexity—Roche holds a 12% pre-IPO stake with pro-rata rights through Series C, limiting future financing flexibility. Second, Hemab's Factor XI mechanism competes with Bristol Myers Squibb's milvexian, now in Phase 3 with 8,000-patient enrollment, establishing both proof-of-concept and competitive pressure. Third, both companies carry preclinical pipeline assets—Seaport's anxiety program SPI-81 and Hemab's stroke-prevention candidate HMB-003—that are unfunded beyond animal studies but appear in valuation discussions. The risk is execution. Seaport's depression trial uses a 16-week endpoint, longer than typical antidepressant studies, raising trial-failure risk if dropout rates exceed 25%. Hemab's coagulation pathway requires bleeding-event monitoring across 52 weeks, extending cash-burn duration.
Watch for three signals. First, book-building results by April 1—any downward pricing revision below the $12-$14 midpoint for Seaport or $10-$12 for Hemab indicates weak institutional demand. Second, topline data readouts: Seaport's MDD trial in Q3 and Hemab's VTE study in Q4 will validate or crater these bets within nine months. Third, the Form 4 filings post-lockup—both companies impose standard 180-day lockups, with expiration mid-October, when founder and VC selling pressure typically emerges. Seaport's insider ownership sits at 68% pre-offering, Hemab's at 71%, both high enough to trigger meaningful supply at unlock.
The dual offering arrives as biotech IPO returns have averaged negative 18% from pricing through twelve months over the past three years, per Renaissance Capital. Seaport and Hemab are betting that late-stage assets and clear catalysts justify entry before that window closes again.
The takeaway
Twin $180M biotech IPOs test Q2 market appetite with depression and clotting candidates facing nine-month data catalysts and October lockup expirations.
Want the 60-second program for your specific event?
Enter your event and email — we build it and send the branded proposal before lunch. No obligation.
The branded-identity layer Chiefs of Staff and heritage CMOs route through — your name imprinted on real authorized stock, your pick of 200+ brands and 70,000 products, shipped from one accountable house. Nine editorial desks publish the intelligence those operators read before they sign.
200+authorized brands
70,000products · virtual proof on each
9 deskspublishing daily
1997one house, since
70,000 SKUs · virtual proof in 60 seconds · no platform fee · blind-shipped · ASI #217876
Your next customer won't visit your website. Their AI will.
AI assistants have quietly taken over the first step of buying — they answer from catalogs they can read and shortlist whoever can actually ship. Two questions now decide whether you exist to that buyer: can a machine read your catalog, and can you fulfill the order. Most brands fail one or both and never find out why the orders went elsewhere. The winners of this shift aren't the loudest. They're the most readable. Build for the machine that's about to do the shopping.
Built by the craft floor — apparel, media, packaging, and secure print.
This trade runs on hands, not desks. Imprint manufacturing & Komori heritage press through approved vendors · Canon high-speed secure-media operations is a craft floor — genuine Six Sigma discipline applied to ink, thread, foil, and registration, where a hundredth of an inch is the difference between a brand that reads serious and one that reads cheap. POPS4 is built by exactly those operators: independent, boots-on-the-ground engineers who carry their own book, read a client in microseconds, and put their name on every run. Beyond our own Virginia Beach floor, we work with a vetted network of craft manufacturers across the US — each meeting the highest excellence in QC standards in the industry, each a specialist in its own discipline — so apparel, hard-goods imprinting, media manufacturing, packaging, and secure printing all go to the bench built for them, coordinated from one accountable hub. Short-run from twenty-five units, volume to five hundred thousand. Two hundred authorized national brands, seventy thousand SKUs with virtual proofing on every one. Art archived for instant reorders. Net-thirty corporate terms, NDA-standard white-label — your name on the work, or none at all.
Strategy, positioning, identity, creative, and messaging — wired into an AI system that publishes and distributes on its own. Nine editorial desks generate the authority, the production house ships the physical proof, and the attribution layer tells you which post sold which SKU. What you get is an operating layer — content, catalog, and order path under one roof — that keeps working whether or not you are in the room. Built for principals who would rather own the machine than rent the agency.
Named-account programs — one desk, quiet delivery, NDA-standard.
One point of contact who already knows the file, so nothing restarts from zero between engagements. The work ships blind, under NDA, with your name on it or none at all. Built for single-family offices, heritage-house CMOs, sports-ownership groups, and the agencies that white-label our production. The relationship is the product; the merch is the proof of it.
SFO · Chief of Staff desk. Principal household, properties, aircraft, yacht, calendar, philanthropy — one file.
Shop seventy thousand products. Virtual proof on every one. 24/7.
Drop your logo on any product and see the virtual proof before asking. Quote routes direct to the desk. MCP catalog for AI agents. Celeste for the fast conversation. Full self-service checkout in development.